Together this may explain the poor prognosis of peritumoral TLS of ccRCC and attempts to reinvigorate the PD‐1+CD8+ T cells and challenge the suppressive TME may increase patients’ sensitivity to the current immunotherapy. Here, CD8A is linked to nonpapillary renal cell carcinoma.